Azione 18H PREVECEUTICAL MEDICAL INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue PreveCeutical Medical Inc. Deutsche Boerse AG

Azioni

18H

CA74141E1043

Mercato chiuso - Deutsche Boerse AG
Altri mercati azionari
 15:45:29 03/05/2024 		Variaz. 5gg Var. 1 gen.
0,019 EUR +80,95% Grafico intraday di PreveCeutical Medical Inc. +26,67% +35,71%
2023 PreveCeutical Medical Inc. inizia la preparazione dello studio preclinico per le sue malattie e ottiene la prova di concetto del programma di terapia genica duale CI
2023 PreveCeutical Medical Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023 CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
PreveCeutical Announces Management Cease Trade Order
PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding
PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program
PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
PreveCeutical & Endosane Announce Update on Intranasal CBD Application
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application
PreveCeutical Medical Inc. Showcases Dynamic Evolution in AI Strategy
PreveCeutical Medical : Showcases Dynamic Evolution in AI Strategy
PreveCeutical Engages New to the Street for Production and Broadcasting Services
PreveCeutical Medical : Engages New to the Street for Production & Broadcasting Services
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
PrevCeutical Medical Provides Update
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia
PreveCeutical Medical : Files Cyclic Peptides And Uses Thereof in the EU and Australia
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use and Cyclic Peptides and Uses Thereof
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
PreveCeutical Medical : Files Two Family Patents of Sol-Gel Cannabinoid Formulation And Antiviral Use & Cyclic Peptides And Uses Thereof
Preveceutical Medical Inc. Furthering the Progress of Its Patent Family Directed to Sol-Gel
PreveCeutical Medical : Sol-Gel and Uses thereof Patent Update
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione PREV
  4. Azione 18H
  5. Notizie PreveCeutical Medical Inc.
  6. Altre lingue